Past, Present, and Future of Familial Hypercholesterolemia Management
By: Viviane Z. Rocha and Raul D. Santos
References
- Defesche JC, Gidding SS, Harada-Shiba M, Hegele RA, Santos RD, Wierzbicki AS. Familial hypercholesterolaemia. Nat Rev Dis Primers. 2017 Dec 7;3:17093. doi: 10.1038/nrdp.2017.93
- Miname MH, Santos RD. Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management. Prog Cardiovasc Dis. Sep-Oct 2019;62(5):414–422. doi: 10.1016/j.pcad.2019.10.003
- Versmissen J, Oosterveer DM, Yazdanpanah M, et al. Efficacy of statins in familial hypercholesterolaemia: a long term cohort study. BMJ. 2008 Nov 11;337:a2423. doi: 10.1136/bmj.a2423
- Hu P, Dharmayat KI, Stevens CAT, et al. Prevalence of Familial Hypercholesterolemia Among the General Population and Patients With Atherosclerotic Cardiovascular Disease: A Systematic Review and Meta-Analysis. Circulation. 2020;141(22):1742–59
- Beheshti SO, Madsen CM, Varbo A, Nordestgaard BG. Worldwide Prevalence of Familial Hypercholesterolemia: Meta-Analyses of 11 Million Subjects. J Am Coll Cardiol. 2020 May 26;75(20):2553–2566. doi: 10.1016/j.jacc.2020.03.057
- Khera AV, Hegele RA. What Is Familial Hypercholesterolemia, and Why Does It Matter? Circulation. 2020 Jun 2;141(22):1760–1763. doi: 10.1161/CIRCULATIONAHA.120.046961
- Khera AV, Won HH, Peloso GM, et al. Diagnostic Yield and Clinical Utility of Sequencing Familial Hypercholesterolemia Genes in Patients With Severe Hypercholesterolemia. J Am Coll Cardiol. 2016 Jun 7;67(22):2578–89. doi: 10.1016/j.jacc.2016.03.520
- Talmud PJ, Shah S, Whittall R, et al. Use of low-density lipoprotein cholesterol gene score to distinguish patients with polygenic and monogenic familial hypercholesterolaemia: a case-control study. Lancet. 2013 Apr 13;381(9874):1293–301. doi: 10.1016/S0140–;6736(12)62127–8
- Santos RD, Stein EA, Hovingh GK, et al. Long-Term Evolocumab in Patients With Familial Hypercholesterolemia. J Am Coll Cardiol. 2020 Feb 18;75(6):565–574. doi: 10.1016/j.jacc.2019.12.020
- Santos RD, Gidding SS, Hegele RA, et al. Defining severe familial hypercholesterolaemia and the implications for clinical management: a consensus statement from the International Atherosclerosis Society Severe Familial Hypercholesterolemia Panel. Lancet Diabetes Endocrinol. 2016 Oct;4(10):850–61. doi: 10.1016/S2213–;8587(16)30041–9
- Libby P, Buring JE, Badimon L, et al. Atherosclerosis. Nat Rev Dis Primers. 2019 Aug 16;5(1):56. doi: 10.1038/s41572–;019-0106-z
- Ference BA, Ginsberg HN, Graham I, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J. 2017 Aug 21;38(32):2459–2472. doi: 10.1093/eurheartj/ehx144
- Berberich AJ, Hegele RA. The complex molecular genetics of familial hypercholesterolaemia. Nat Rev Cardiol. 2019 Jan;16(1):9–20. doi: 10.1038/s41569–;018-0052–6
- Brinton EA, Hopkins PN, Hegele RA, et al. The association between hypercholesterolemia and sitosterolemia, and report of a sitosterolemia kindred. J Clin Lipidol. 2013 Aug;24(4):332–8. doi: 10.1097/MOL.0b013e328361f6c6
- Fouchier SW, Defesche JC. Lysosomal acid lipase A and the hypercholesterolaemic phenotype. Curr Opin Lipidol. 2013 Aug;24(4):332–8. doi: 10.1097/MOL.0b013e328361f6c6
- Mohebi R, Chen Q, Hegele RA, Rosenson RS. Failure of cosegregation between a rare STAP1 missense variant and hypercholesterolemia. J Clin Lipidol. Sep-Oct 2020;14(5):636–638. doi: 10.1016/j.jacl.2020.07.010
- Loaiza N, Hartgers ML, Reeskamp LF, et al. Taking One Step Back in Familial Hypercholesterolemia: STAP1 Does Not Alter Plasma LDL (Low-Density Lipoprotein) Cholesterol in Mice and Humans. Arterioscler Thromb Vasc Biol. 2020 Apr;40(4):973–985. doi: 10.1161/ATVBAHA.119.313470
- Trinder M, Li X, DeCastro ML, et al. Risk of Premature Atherosclerotic Disease in Patients With Monogenic Versus Polygenic Familial Hypercholesterolemia. J Am Coll Cardiol. 2019 Jul 30;74(4):512–522. doi: 10.1016/j.jacc.2019.05.043
- Gidding SS, Champagne MA, de Ferranti SD, et al. The Agenda for Familial Hypercholesterolemia: A Scientific Statement From the American Heart Association. Circulation. 2015 Dec 1;132(22):2167–92. doi: 10.1161/CIR.0000000000000297
- Wang J, Dron JS, Ban MR, et al. Polygenic Versus Monogenic Causes of Hypercholesterolemia Ascertained Clinically. Arterioscler Thromb Vasc Biol. 2016 Dec;36(12):2439–2445. doi: 10.1161/ATVBAHA.116.308027
- Sturm AC, Knowles JW, Gidding SS, et al. Clinical Genetic Testing for Familial Hypercholesterolemia: JACC Scientific Expert Panel. J Am Coll Cardiol. 2018 Aug 7;72(6):662–680. doi: 10.1016/j.jacc.2018.05.044
- Hendricks-Sturrup RM, Lu CY. Understanding Implementation Challenges to Genetic Testing for Familial Hypercholesterolemia in the United States. J Pers Med. 2019 Feb 1;9(1):9. doi: 10.3390/jpm9010009
- Chapman CR, Mehta KS, Parent B, Caplan AL. Genetic discrimination: emerging ethical challenges in the context of advancing technology. J Law Biosci. 2019 Dec 5;7(1):lsz016. doi: 10.1093/jlb/lsz016
- Klancar G, Groselj U, Kovac J, et al. Universal Screening for Familial Hypercholesterolemia in Children. J Am Coll Cardiol. 2015 Sep 15;66(11):1250–1257. doi: 10.1016/j.jacc.2015.07.017
- Wald DS, Bestwick JP, Morris JK, Whyte K, Jenkins L, Wald NJ. Child-Parent Familial Hypercholesterolemia Screening in Primary Care. N Engl J Med. 2016 Oct 27;375(17):1628–1637. doi: 10.1056/NEJMoa1602777
- Humphries SE, Cooper JA, Seed M, et al. Coronary heart disease mortality in treated familial hypercholesterolaemia: Update of the UK Simon Broome FH register. Atherosclerosis. 2018 Jul;274:41–46. doi: 10.1016/j.atherosclerosis.2018.04.040
- Mundal L, Igland J, Ose L, et al. Cardiovascular disease mortality in patients with genetically verified familial hypercholesterolemia in Norway during 1992–2013. Eur J Prev Cardiol. 2017 Jan;24(2):137–144. doi: 10.1177/2047487316676135
- Alves AC, Alonso R, Diaz-Diaz JL, et al. Phenotypical, Clinical, and Molecular Aspects of Adults and Children With Homozygous Familial Hypercholesterolemia in Iberoamerica. Arterioscler Thromb Vasc Biol. 2020 Oct;40(10):2508–2515. doi: 10.1161/ATVBAHA.120.313722
- Thompson GR, Blom DJ, Marais AD, Seed M, Pilcher GJ, Raal FJ. Survival in homozygous familial hypercholesterolaemia is determined by the on-treatment level of serum cholesterol. Eur Heart J. 2018 Apr 7;39(14):1162–1168. doi: 10.1093/eurheartj/ehx317
- de Isla LP, Alonso R, Mata N, et al. Predicting Cardiovascular Events in Familial Hypercholesterolemia: The SAFEHEART Registry (Spanish Familial Hypercholesterolemia Cohort Study). Circulation. 2017 May 30;135(22):2133–2144. doi: 10.1161/CIRCULATIONAHA.116.024541
- Miname MH, Bittencourt MS, Moraes SR, et al. Coronary Artery Calcium and Cardiovascular Events in Patients With Familial Hypercholesterolemia Receiving Standard Lipid-Lowering Therapy. JACC Cardiovasc Imaging. 2019 Sep;12(9):1797–1804. doi: 10.1016/j.jcmg.2018.09.019
- Silva PR, Jannes CE, Marsiglia JD, Krieger JE, Santos RD, Pereira AC. Predictors of cardiovascular events after one year of molecular screening for Familial hypercholesterolemia. Atherosclerosis. 2016 Jul;250:144–50. doi: 10.1016/j.atherosclerosis.2016.05.023
- Coutinho ER, Miname MH, Rocha VZ, et al. Familial hypercholesterolemia and cardiovascular disease in older individuals. Atherosclerosis. 2021 Feb;318:32–37. doi: 10.1016/j.atherosclerosis.2020.12.012
- Langsted A, Kamstrup PR, Benn M, Tybjaerg-Hansen A, Nordestgaard BG. High lipoprotein(a) as a possible cause of clinical familial hypercholesterolaemia: a prospective cohort study. Lancet Diabetes Endocrinol. 2016 Jul;4(7):577–87. doi: 10.1016/S2213–;8587(16)30042–0
- Paquette M, Brisson D, Dufour R, Khoury E, Gaudet D, Baass A. Cardiovascular disease in familial hypercholesterolemia: Validation and refinement of the Montreal-FH-SCORE. J Clin Lipidol. Sep-Oct 2017;11(5):1161–1167.e3. doi: 10.1016/j.jacl.2017.07.008
- Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2019 Jun 25;73(24):e285–e350. doi: 10.1016/j.jacc.2018.11.003
- Gallo A, Charriere S, Vimont A, et al. SAFEHEART risk-equation and cholesterol-year-score are powerful predictors of cardiovascular events in French patients with familial hypercholesterolemia. Atherosclerosis. 2020 Aug;306:41–49. doi: 10.1016/j.atherosclerosis.2020.06.011
- Humphries SE, Cooper JA, Capps N, et al. Coronary heart disease mortality in severe vs. non-severe familial hypercholesterolaemia in the Simon Broome Register. Atherosclerosis. 2019 Feb;281:207–212. doi: 10.1016/j.atherosclerosis.2018.11.014
- Gallo A, Perez de Isla L, Charrière S, et al. The Added Value of Coronary Calcium Score in Predicting Cardiovascular Events in Familial Hypercholesterolemia. JACC Cardiovasc Imaging. 2021 Jul 8;S1936–878X(21)00501–5. doi: 10.1016/j.jcmg.2021.06.011
- Mszar R, Grandhi GR, Valero-Elizondo J, et al. Absence of Coronary Artery Calcification in Middle-Aged Familial Hypercholesterolemia Patients Without Atherosclerotic Cardiovascular Disease. JACC Cardiovasc Imaging. 2020 Apr;13(4):1090–1092. doi: 10.1016/j.jcmg.2019.11.001
- Perez de Isla L, Alonso R, Watts GF, et al. Attainment of LDL-Cholesterol Treatment Goals in Patients With Familial Hypercholesterolemia: 5-Year SAFEHEART Registry Follow-Up. J Am Coll Cardiol. 2016 Mar 22;67(11):1278–85. doi: 10.1016/j.jacc.2016.01.008
- Alonso R, Muniz-Grijalvo O, Diaz-Diaz JL, et al. Efficacy of PCSK9 inhibitors in the treatment of heterozygous familial hypercholesterolemia: A clinical practice experience. J Clin Lipidol. 2021 May 7;S1933–2874(21)00069–6. doi: 10.1016/j.jacl.2021.04.011
- Mszar R, Nasir K, Santos RD. Coronary Artery Calcification in Familial Hypercholesterolemia: An Opportunity for Risk Assessment and Shared Decision Making With the Power of Zero? Circulation. 2020 Oct 13;142(15):1405–1407. doi: 10.1161/CIRCULATIONAHA.120.049057
- Raal FJ, Kallend D, Ray KK, et al. Inclisiran for the Treatment of Heterozygous Familial Hypercholesterolemia. N Engl J Med. 2020 Apr 16;382(16):1520–1530. doi: 10.1056/NEJMoa1913805
- Stefanutti C, Thompson GR. Lipoprotein apheresis in the management of familial hypercholesterolaemia: historical perspective and recent advances. Curr Atheroscler Rep. 2015 Jan;17(1):465. doi: 10.1007/s11883–;014-0465–6
- Raal FJ, Rosenson RS, Reeskamp LF, et al. Evinacumab for Homozygous Familial Hypercholesterolemia. N Engl J Med. 2020 Aug 20;383(8):711–720. doi: 10.1056/NEJMoa2004215
- Rosenson RS, Burgess LJ, Ebenbichler CF, et al. Evinacumab in Patients with Refractory Hypercholesterolemia. N Engl J Med. 2020 Dec 10;383(24):2307–2319. doi: 10.1056/NEJMoa2031049
- Rodriguez-Calvo R, Masana L. Review of the scientific evolution of gene therapy for the treatment of homozygous familial hypercholesterolaemia: past, present and future perspectives. J Med Genet. 2019 Nov;56(11):711–717. doi: 10.1136/jmedgenet-2018–;105713
- Wilemon KA, Patel J, Aguilar-Salinas C, et al. Reducing the Clinical and Public Health Burden of Familial Hypercholesterolemia: A Global Call to Action. JAMA Cardiol. 2020 Feb 1;5(2):217–229. doi: 10.1001/jamacardio.2019.5173
DOI: https://doi.org/10.14797/mdcvj.887 | Journal eISSN: 1947-6108
Language: English
Page range: 28 - 35
Submitted on: Jul 14, 2021
Accepted on: Jul 16, 2021
Published on: Sep 24, 2021
Published by: Houston Methodist DeBakey Heart & Vascular Center
In partnership with: Paradigm Publishing Services
Keywords:
© 2021 Viviane Z. Rocha, Raul D. Santos, published by Houston Methodist DeBakey Heart & Vascular Center
This work is licensed under the Creative Commons Attribution-NonCommercial 4.0 License.